{'fraction_non_alphanumeric': 0.046232876712328765, 'fraction_numerical': 0.019691780821917807, 'mean_word_length': 5.718390804597701, 'pattern_counts': {'":': 0, '<': 4, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Dr antigen positive monocyte‐macrophages control granulocyte‐macrophage colony‐stimulating activity and burst promoting activity elaboration in man

To investigate the mechanisms that modulate granulocyte‐macrophage colony‐stimulating activity (GM‐CSA) and burst promoting activity (BPA) elaboration, we studied human peripheral blood‐derived monocyte‐macrophage (MØ) and T‐lymphocyte (TL) interaction. Coincubation of live MØ with autologous TL at a 1:3 ratio in the presence of 1% phytohemagglutinin synergistically increased GM‐CSA (6 of 6 experiments) and BPA (4 of 6 experiments) (P <0.002). Prior treatment of MØ with cycloheximide or actinomycin D significantly (P < 0.002) diminished this MØ's capacity to collaborate with TL. Mitomycin C treatment did not. Live MØ also enhanced TL‐derived GM‐CSA (P <0.002) and BPA (P <0.001). This enhancement was again compromised by prior cycloheximide or actinomycin D treatment, but not by mitomycin C treatment. Further experiments in which we blocked DR antigen on MØ membrane with monoclonal anti‐DR antibodies suggested that MØ required their membrane DR antigen to collaborate with TL in elaborating GM‐CSA and BPA.